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recommendations for hepatitis B virus (HBV) and hepatitis C virus (HCV) have not been produced given a lack of UK evidence to support routine testing in this setting. 4 The aim of this study was to estimate undiagnosed BBV prevalence in three urban EDs in different areas of England to inform testing strategies.
| ME THODS
Standardized unlinked anonymous BBV prevalence surveys were conducted using residual biochemistry blood from ED attendees at three sites in England: two London hospitals in the southeast of England (Charing Cross (CXH) and St Mary's (SMH)) and one city in the northwest of England (Liverpool). Unselected deduplicated lists of ED U&E blood samples for inclusion in the study were generated using laboratory information systems. Inclusion criteria were (a) age 16-65 years and (b) ≥0.75 mL surplus serum in the primary blood tube. Previously diagnosed BBV prevalence in this cohort was estimated through interrogation of local health care IT records to report the aggregate number of diagnosed infections. Individual routine pathology results were not retained. Samples were then irreversibly anonymized except for sex, age and ethnicity prior to screening for hepatitis B surface antigen (HBsAg), HCV antibody and HIV antigen/antibody. Positive results were confirmed using neutralization, RNA and lineblot assays. Active infection was defined as HBsAg that was either neutralizable or confirmed on a second assay, HCV RNA ≥15 IU/mL, HIV antigen/antibody confirmed with two different immunoassays or HIV-1 RNA. The study population is described in greater detail in the supporting information (Table S1 ).
| RE SULTS
Overall active BBV infection prevalence in the total study population was 3.3% (95% confidence interval [CI] 2.8%-3.8%). Of these, 101/150 (67.3%) were undiagnosed according to local databases 
| D ISCUSS I ON
To our knowledge, this study is the largest multicentre anonymous BBV data set from UK ED attendees. We demonstrate a consistently high active BBV prevalence at all urban ED sites (3.3% [range 2.7%-4.0%]), and the results confirm those of an earlier HCV study adding weight to the case for systematic BBV testing in this population. 5 Of particular importance given existing public health objectives was that two thirds of active infections were estimated to be locally undiagnosed.
Our overall HIV prevalence findings are in line with those reported in previous UK studies, although the proportion of previously undiagnosed infections was higher (0.8% vs 0.3%). 6 This may reflect the limitation of using local databases for prior diagnosis but also local demographic variation or chance.
National BBV surveillance is coordinated through Public Health
England with ED data accounting for a small proportion of this Laboratory BBV test tariffs vary considerably between providers in the UK. When including resolution of false positives and using averaged standard tariffs, laboratory costs per active diagnosis in our study were £663 HCV, £563 HBV and £1277 HIV (Table S2 ).
Laboratory assay cost will have a key impact on high-volume ED testing. However, savings are likely achievable through price-volume and test bundle agreements. Further work is underway to estimate cost-effectiveness of systematic testing in the English EDs. 9 Testing in this area is not without challenge given the high pressure on staff time and potential costs involved. However, there is substantial US and emerging UK evidence of the effectiveness of electronic patient record (EPR) triggered ED BBV screening programmes and that subsequent engagement with the care cascade can be effective and sustainable. 3, 8 Molecular platforms now facilitate near-patient nucleic acid testing, and results can be available within NHS ED waiting time targets. 10 Coupled with improved therapy options, the environment now exists for new pathways to be considered for increased diagnosis and rapid linkage to care.
Our study has a number of limitations. Our study used routinely collected ED data and was not designed to collect clinical data or other risk factors such as homelessness or injecting drug use. Further, our data pertain to populations triaged for a blood draw which may differ from low-risk patients attending for minor injuries. 10 Conversely, the requirement for surplus serum might add a bias against patients with poor venous access such as PWID, although this would have led to our results representing an underestimate. The anonymous study model relied on local healthcare databases for known prevalence estimates, so prior diagnosis in another healthcare service using different laboratories cannot be excluded. However, we feel this would apply less to the undiagnosed prevalence in the more unitary healthcare economies outside London. Importantly, prior diagnosis does not equate to engagement with care which is especially relevant for HCV and marginalized populations in general. Testing in the ED provides an opportunity to re-diagnose and re-engage for treatment.
Whilst our aim was primarily to inform viral hepatitis ED epidemiology, and our site sample size therefore sufficiently powered for HCV and HBV, we acknowledge it was likely underpowered to precisely estimate HIV prevalence.
Our multicentre results support emerging evidence that urban ED BBV testing initiatives could provide a valuable contribution to improve diagnosis and linkage to care pathways in England. We recommend that testing strategies are informed by local prevalence data if WHO targets are to be achieved.
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